1
Clinical Trials associated with H7N9 antigen Adjuvanted With IB160(Butantan Institute)A Phase I Randomized, Double-blind, Placebo-controlled, Dose Finding Clinical Trial to Evaluate the Safety and Immunogencity of H7N9 Influenza Antigen Adjuvanted With 2 Different Adjuvant Formulations in Healthy Adult Volunteers in Brazil
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .
100 Clinical Results associated with H7N9 antigen Adjuvanted With IB160(Butantan Institute)
100 Translational Medicine associated with H7N9 antigen Adjuvanted With IB160(Butantan Institute)
100 Patents (Medical) associated with H7N9 antigen Adjuvanted With IB160(Butantan Institute)
100 Deals associated with H7N9 antigen Adjuvanted With IB160(Butantan Institute)